Embla Medical hf.

OSSFFOTCHealthcare● Active

$5.11

+$0.96(+23.13%)

Market Cap$2.2B

P/E Ratio—

52W High$5.325

52W Low$4.15

Avg Volume82

Open$5.11

Beta0.46

Free Cash Flow Financials Revenue

Embla Medical hf. (OSSFF) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

OSSFF · free cash flow · updated Jun 9, 2026

Core FCF metrics

OSSFF · FCF · TTM · margin & CAGR

Free cash flow was $118.9M for FY2025 (fiscal year ending 2025-12-31), up 54.8% year-over-year The FCF margin was 12.3%. Five-year CAGR stands at +11.8%.

FY2025 Free Cash Flow$118.9M▲ +54.8% YoY

Trailing 12M (TTM)$108.6Mtrailing 4 quarters sum

FCF Margin12.3%$118.9M ÷ revenue

3-Year CAGR+50.6%FY2022 → FY2025

5-Year CAGR+11.8%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

OSSFF · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$141.8M(23M)$118.9M▲ +54.8%12.3%

FY2024$116.1M(39M)$76.8M▲ +47.6%9.0%

FY2023$94.3M(42M)$52.0M▲ +49.4%6.6%

FY2022$60.8M(26M)$34.8M▼ 52.8%4.8%

FY2021$100.5M(27M)$73.8M▲ +8.2%10.3%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

OSSFF · P/FCF · FCF yield · FCF per share

Embla Medical hf. (OSSFF) trades at a FCF yield of 6.18% and a price-to-free-cash-flow ratio of 20.4x. FCF per share stands at $0.25, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

6.18%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$0.25

TTM FCF ÷ Shares Outstanding

Price / FCF

x20.4

Share Price ÷ FCF per Share

EV / FCF (TTM)

x20.4

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

OSSFF · cash flow statement · operating / investing / financing

For FY2025, Embla Medical hf. generated $141.8M in operating cash flow and spent 23M in capital expenditures, yielding $118.9M in free cash flow.

Operating Activities

+$141.8M

Cash from core business operations

2025-12-31

Investing Activities

−$57.4M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$72.3M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($141.8M) − |CapEx| (23M) = FCF ($118.9M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

OSSFF vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Embla Medical hf.YOU

OSSFF

$118.9M+54.8%12.3%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Embla Medical hf. (OSSFF) reported free cash flow of $118.9M for FY2025 (fiscal year ending 2025-12-31), up 54.8% year-over-year. The FCF margin was 12.3%.

Based on available data, Embla Medical hf. has maintained positive free cash flow for at least 15 fiscal year(s). FCF peaked at $118.9M in FY2025. The 5-year CAGR stands at +11.8%.

Embla Medical hf.'s FCF yield is 6.18% and price-to-FCF ratio is 20.4x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

OSSFF free cash flow · 8 questions

Embla Medical hf. free cash flow was $118.9M for FY2025, up 54.8% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $108.6M.

OSSFF free cash flowOSSFF FCFOSSFF FCF 2025OSSFF free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Embla Medical hf. · Embla Medical hf. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026